Anixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial

Core Viewpoint - Anixa Biosciences is advancing its Phase 1 clinical trial of a novel CAR-T therapy for ovarian cancer, with the sixth patient treated in the second dosage cohort, potentially leading to the enrollment of a third cohort soon if safety continues to be confirmed [1][2]. Group 1: Clinical Trial Progress - The sixth patient treated is expected to be the last in the second dosage cohort, with plans to escalate to a third cohort if no adverse effects are observed [1]. - The second cohort received triple the dose of CAR-T cells compared to the first cohort, with no dose-limiting toxicities reported [2]. - The trial will begin enrolling patients in the third dose cohort at a ten times higher dose than the initial dosage after a one-month wait for safety confirmation [3]. Group 2: Technology and Mechanism - Anixa's CAR-T technology targets the follicle-stimulating hormone receptor (FSHR), which is exclusively expressed on ovarian cells, including tumor vasculature [2]. - The therapy aims to utilize a dual mechanism of action by targeting tumor vasculature and ovarian cells, potentially making CAR-T effective in solid tumors like ovarian cancer [4]. - The intraperitoneal (IP) delivery method is expected to enhance targeting and improve the safety profile by minimizing side effects such as cytokine release syndrome [4]. Group 3: Company Overview - Anixa is a clinical-stage biotechnology company focused on cancer treatment and prevention, with a portfolio that includes an ovarian cancer immunotherapy program developed in collaboration with Moffitt Cancer Center [5]. - The company is also developing vaccines for triple negative breast cancer and other cancers, utilizing a unique business model that partners with renowned research institutions [5].